21 43

Cited 7 times in

Korean Society of infectious diseases/national evidence-based healthcare collaborating agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19

Authors
 Sun Bean Kim  ;  Jimin Kim  ;  Kyungmin Huh  ;  Won Suk Choi  ;  Yae Jean Kim  ;  Eun Jeong Joo  ;  Youn Jeong Kim  ;  Young Kyung Yoon  ;  Jung Yeon Heo  ;  Yu Bin Seo  ;  Su Jin Jeong  ;  Su Yeon Yu  ;  Kyong Ran Peck  ;  Miyoung Choi  ;  Joon Sup Yeom  ;  Korean Society of Infectious Diseases (KSID) 
Citation
 INFECTION AND CHEMOTHERAPY, Vol.53(2) : 395-403, 2021-06 
Journal Title
INFECTION AND CHEMOTHERAPY
ISSN
 2093-2340 
Issue Date
2021-06
Keywords
Anti-SARS-CoV-2 monoclonal antibody ; COVID-19 ; Korea
Abstract
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
Files in This Item:
T992021119.pdf Download
DOI
10.3947/IC.2021.0304
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Jeong, Su Jin(정수진) ORCID logo https://orcid.org/0000-0003-4025-4542
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/196683
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links